Posted by Michael Wonder on 11 Feb 2022
AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and Manitoba are the first provinces to reimburse the combination treatment for newly diagnosed acute myeloid leukaemia patients who are ineligible for intensive induction chemotherapy.
AbbVie announced today that an agreement was reached with the pan-Canadian Pharmaceutical Alliance for Venclexta (venetoclax) in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukaemia who are 75 years or older, or who have co-morbidities that preclude use of intensive induction chemotherapy.
